Inspired by the “Amyloid Cascade Hypothesis” a number of pharmaceutical companies have dedicated time and efforts to develop pipelines and accelerate the introduction of small-molecule BACE1 inhibitors as potential disease modifying therapies for AD. The gene discussed is BACE1; the disease is Alzheimer disease.